Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NKTR-102 q14d · 1 trial · 2 indications
The ORR was defined as the proportion of patients with a complete response (CR) or a partial response (PR) per RECIST 1.0 based upon the best response as assessed by the Investigator. CR was defined by RECIST 1.1 as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have had reduction in short axis to \<10 mm. PR was defined by RECIST 1.1 as at least a 30% decrease in the sum of the diameters (SOD) of target lesions, taking as reference the baseline SOD. The analysis was performed for patients in the Primary Efficacy Population.
| Arm | Type | Description |
|---|---|---|
| NKTR-102 q14d | EXPERIMENTAL | NKTR-102 was administered as an intravenous (IV) infusion over 90 ± 10 minutes, on Day 1 of each 2-week \[± 2 days\] cycle at a dose of 170 mg/m\^2 for the first 4 patients enrolled and at a dose of 145 mg/m\^2 for the remainder of the patients. |
| NKTR-102 q21d | EXPERIMENTAL | NKTR-102 was administered as an IV infusion over 90 ± 10 minutes, on Day 1 of each 3-week \[± 2 days\] cycle at a dose of 170 mg/m\^2 for the first 6 patients enrolled and at a dose of 145 mg/m\^2 for the remainder of the patients. |
| Name | Type | Description |
|---|---|---|
| NKTR-102 q14d | DRUG | NKTR-102 given on a q14 day schedule |
| NKTR-102 q21d | DRUG | NKTR-102 given on a q21 day schedule |
Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer 2. Inoperable metastatic or locally advanced ovarian cancer 3. Platinum-resistant ovarian cancer defined as progression by RECIST within 6 mont...
Top 20 of 45 competitors
NKTR-102 q14d is an investigational small molecule being studied for the treatment of tumors, specifically metastatic or locally advanced ovarian cancer. It is administered on a 14-day schedule. The drug is in Phase 2 clinical development and is not yet approved by regulatory authorities.
NKTR-102 q14d is being developed by Nektar Therapeutics, a biopharmaceutical company traded on the NASDAQ under the ticker symbol NKTR. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational oncology drug.
NKTR-102 q14d is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is being studied for its potential use in treating patients with metastatic or locally advanced ovarian cancer.
NKTR-102 q14d has been studied in one completed Phase 2 clinical trial, identified as NCT00806156. This trial evaluated the safety and efficacy of the drug in 178 female patients with metastatic or locally advanced ovarian cancer. The study was conducted in the United States, Belgium, and the United Kingdom.
NKTR-102 q14d is a small molecule oncology drug. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being evaluated for its ability to treat tumors, particularly ovarian cancer, through a mechanism that is the subject of ongoing clinical investigation.